Intensity Therapeutics Inc (INTS) Stock Price, Quote & News

Company Profile

Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Co...

Industry: Biotechnology

Sector: Healthcare

Phone: 203 221 7381

Fax: 203 557 3023

Website: intensitytherapeutics.com

Address:

1 Enterprise Drive, Suite 430, Shelton, United States

Jimmyjabba Jun. 4 at 8:07 PM

$INTS I made money on this one a day spike, then a few weeks later bought more. Stupid. This is never going anywhere besides another reverse split. All these biotech the same. Lole a slodomg board. What a waste.

1 · Reply

Eric1072 Jun. 4 at 3:26 PM

$INTS will buy back in below $2

0 · Reply

Atrain1189 Jun. 4 at 3:19 PM

$INTS what a complete shit show

0 · Reply

SBEEE Jun. 4 at 12:54 AM

$INTS people should bring some of their profits from $SNDK &. $MU, One day INTS is going to be on top with proven Cancer treatment.

1 · Reply

Pettechfl Jun. 4 at 12:23 AM

$INTS whats going on today?

0 · Reply

SBEEE Jun. 3 at 11:30 AM

$INTS Right time for INTS to show performance if CEO is not a vacation anymore. https://finance.yahoo.com/sectors/healthcare/articles/abivax-drops-32-cancer-cases-192613427.html

0 · Reply

SBEEE Jun. 2 at 8:17 PM

$INTS https://www.biopharmaboardroom.com/interaction/1/4546/reprogramming-the-tumor-lew-bender-on-engineering-a-new-paradigm-in-cancer-therapy.html

0 · Reply

Masonic11 May. 29 at 12:02 AM

$ALP Exactly 💯. That girl has the moxy we need!!! The right players, the right industry, the right time. On another note, we need full float disclosure, $TRNX $TRNFQ. This mo fro can explode like noBody business. IP, green technology, oh, Portage cancer molecule, $INTS, $INO Sale. @Stopcapping, @Iggykoopa Shorty, cover before you're a 6th street bitch. Don't be sheep, put shit together. I've been here for 7 years. Muchi is no joke, think about it, 🤔. Zero institutional holdings, to 35++. We partying in south beach, then to Ibeaza. 👽🖕⛱️🍻

2 · Reply

Atrain1189 May. 26 at 6:37 PM

$INTS wen moon

1 · Reply

MilsLearning May. 22 at 7:41 PM

$INTS 🩳🔥🖕

0 · Reply

Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award

2026-05-07T20:50:11.000Z - 4 weeks ago

Intensity Therapeutics reports Q1 EPS (96c), consensus ($1.09)

May 7, 2026, 4:06 PM EDT - 4 weeks ago

Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 7, 2026, 7:00 AM EDT - 4 weeks ago

Intensity Therapeutics Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 4 weeks ago

Intensity Therapeutics Earnings release: Q1 2026

Apr 30, 2026, 8:00 AM EDT - 5 weeks ago

Intensity Therapeutics Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 5 weeks ago

Intensity Therapeutics Proxy statement: Proxy filing

Apr 15, 2026, 9:15 AM EDT - 7 weeks ago

Intensity Therapeutics Recognized with Pinnacle Award for Excellence in Healthcare Innovation

2026-03-30T20:00:12.000Z - 2 months ago

Intensity Therapeutics upgraded to Buy from Hold at Freedom Broker

Mar 27, 2026, 4:12 PM EDT - 2 months ago

Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update

Mar 27, 2026, 7:00 AM EDT - 2 months ago

Intensity Therapeutics Earnings release: Q4 2025

Mar 27, 2026, 7:00 AM EDT - 2 months ago

Intensity Therapeutics Annual report: Q4 2025

2026-03-24T12:12:43.000Z - 2 months ago

Intensity Therapeutics issued new patent in the US

Mar 24, 2026, 8:00 AM EDT - 2 months ago

Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US

2026-03-13T11:12:24.000Z - 2 months ago

Intensity Therapeutics price target adjusted to $30 at Alliance Global

2026-03-12T11:36:30.000Z - 3 months ago

Intensity Therapeutics provides update on INVINCIBLE-4 Study

Mar 12, 2026, 7:30 AM EDT - 3 months ago

Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study

2026-03-06T12:50:53.000Z - 3 months ago

Intensity Therapeutics regains Nasdaq compliance

Mar 6, 2026, 7:47 AM EST - 3 months ago

Intensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price Requirement

2026-02-19T00:50:17.000Z - 3 months ago

Intensity Therapeutics Inc trading halted, news pending

2026-02-13T14:00:18.000Z - 3 months ago

Intensity Therapeutics announces reverse stock split

Feb 13, 2026, 8:58 AM EST - 3 months ago

Intensity Therapeutics Announces Reverse Stock Split

2026-01-13T12:55:38.000Z - 5 months ago

Intensity Therapeutics to ‘opportunistically raise additional capital’ in 2026

Jan 13, 2026, 7:47 AM EST - 5 months ago

Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities

2025-12-11T12:55:17.000Z - 6 months ago

Intensity Therapeutics to present two posters ay SABCS

Dec 11, 2025, 7:47 AM EST - 6 months ago

Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium

2025-12-05T12:35:32.000Z - 6 months ago

Intensity Therapeutics granted 180-day extension to regain Nasdaq compliance

Dec 5, 2025, 7:30 AM EST - 6 months ago

Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement

Dec 4, 2025, 7:47 AM EST - 6 months ago

Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium

2025-11-06T21:52:24.000Z - 7 months ago

Intensity Therapeutics reports Q3 EPS (6c) vs. (25c) last year

Nov 6, 2025, 4:02 PM EST - 7 months ago

Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 6, 2025, 7:00 AM EST - 7 months ago

Intensity Therapeutics Earnings release: Q3 2025

Nov 6, 2025, 7:00 AM EST - 7 months ago

Intensity Therapeutics Quarterly report: Q3 2025

Oct 31, 2025, 9:00 AM EDT - 7 months ago

Intensity Therapeutics Transcript: Study Result

Oct 31, 2025, 9:00 AM EDT - 7 months ago

Intensity Therapeutics Press release: Study Result

2025-10-31T12:10:36.000Z - 7 months ago

Intensity Therapeutics prices 5M shares at 80c in registered direct offering

Oct 31, 2025, 8:00 AM EDT - 7 months ago

Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common Stock

2025-10-30T13:08:35.000Z - 7 months ago

Why Is Intensity Therapeutics Stock (INTS) Up 195% Today?

2025-10-30T11:40:25.000Z - 7 months ago

Intensity Therapeutics’ INT230-6 antitumor effect featured in published study

$Intensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers in eBioMedicine, a Lancet Discovery Science Journal$

Oct 30, 2025, 7:30 AM EDT - 7 months ago

Intensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers in eBioMedicine, a Lancet Discovery Science Journal

Oct 22, 2025, 10:30 AM EDT - 8 months ago

Intensity Therapeutics Transcript: AGM 2025

2025-09-10T11:50:14.000Z - 9 months ago

Intensity Therapeutics pauses new patient enrollment in INVINCIBLE-4 trial

Sep 10, 2025, 7:47 AM EDT - 9 months ago

Intensity Therapeutics Reports INVINCIBLE-4, Presurgical Triple-Negative Breast Cancer Study Update

Sep 9, 2025, 8:00 AM EDT - 9 months ago

Intensity Therapeutics Proxy statement: Proxy Filing

Sep 9, 2025, 8:00 AM EDT - 9 months ago

Intensity Therapeutics Proxy statement: Proxy Filing

Sep 2, 2025, 7:47 AM EDT - 9 months ago

Intensity Therapeutics, Inc. to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 28, 2025, 8:00 AM EDT - 10 months ago

Intensity Therapeutics Proxy statement: Proxy Filing

2025-08-20T11:45:09.000Z - 10 months ago

Intensity Therapeutics price target lowered to $1.50 from $4 at Benchmark

2025-08-12T19:25:20.000Z - 10 months ago

Intensity Therapeutics upgraded to Buy from Hold at Brookline

Aug 12, 2025, 7:47 AM EDT - 10 months ago

Intensity Therapeutics, Inc. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement

Aug 7, 2025, 4:06 PM EDT - 10 months ago

Intensity Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 7, 2025, 4:00 PM EDT - 10 months ago

Intensity Therapeutics Earnings release: Q2 2025

Aug 7, 2025, 4:00 PM EDT - 10 months ago

Intensity Therapeutics Quarterly report: Q2 2025

Aug 4, 2025, 7:47 AM EDT - 10 months ago

Intensity Therapeutics, Inc. Raises $6.6 Million from At The Market Offering (ATM) Stock Sales in July 2025

Jul 17, 2025, 10:30 AM EDT - 11 months ago

Intensity Therapeutics Transcript: AGM 2025

Jun 30, 2025, 8:00 AM EDT - 1 year ago

Intensity Therapeutics, Inc. Announces that INT230-6 Achieved 100% Complete Response Rate in Preclinical Models of Malignant Peripheral Nerve Sheath Tumors (MPNST)

Jun 11, 2025, 11:46 PM EDT - 1 year ago

Intensity Therapeutics, Inc. Announces Pricing of Public Offering

Jun 11, 2025, 4:06 PM EDT - 1 year ago

Intensity Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

Jun 11, 2025, 8:30 AM EDT - 1 year ago

Intensity Therapeutics, Inc. Announces Patients Receiving INT230-6 Prior to the Start of Standard-of-Care May Achieve High Levels of Tumor Necrosis in the Ongoing Randomized Controlled Phase 2 INVINCIBLE-4 Study

Jun 2, 2025, 8:00 AM EDT - 1 year ago

Intensity Therapeutics Proxy statement: Proxy Filing

Jun 2, 2025, 8:00 AM EDT - 1 year ago

Intensity Therapeutics Proxy statement: Proxy Filing

May 29, 2025, 8:00 AM EDT - 1 year ago

Intensity Therapeutics, Inc.'s Phase 3 INVINCIBLE-3 Sarcoma Study Selected for Presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

May 28, 2025, 8:00 AM EDT - 1 year ago

Intensity Therapeutics, Inc. to Collaborate with Author, Model, Executive Producer, Speaker and Breast Cancer Survivor Christine Handy to Raise Patient Awareness of Early-Stage Breast Cancer Treatment Options on the Horizon

May 13, 2025, 4:06 PM EDT - 1 year ago

Intensity Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 12, 2025, 6:00 PM EDT - 1 year ago

Intensity Therapeutics Quarterly report: Q1 2025

May 12, 2025, 6:00 PM EDT - 1 year ago

Intensity Therapeutics Earnings release: Q1 2025

May 6, 2025, 8:00 AM EDT - 1 year ago

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Receive European Medicines Agency Authorization to Initiate Phase 2 INVINCIBLE-4 (SAKK/66/22) Study for INT230-6 in the Treatment of Presurgical Triple-Negative Breast Cancer in France

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Intensity Therapeutics, Inc. Announces $2.35 Million Public Offering

Apr 24, 2025, 8:00 AM EDT - 1 year ago

Intensity Therapeutics Registration statement: Registration Filing

Apr 22, 2025, 8:00 AM EDT - 1 year ago

Intensity Therapeutics Registration statement: Registration Filing

Mar 13, 2025, 4:07 PM EDT - 1 year ago

Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update

Mar 12, 2025, 7:00 PM EDT - 1 year ago

Intensity Therapeutics Annual report: Q4 2024

Mar 12, 2025, 7:00 PM EDT - 1 year ago

Intensity Therapeutics Earnings release: Q4 2024

Jan 28, 2025, 8:00 AM EST - 1 year ago

Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") Following Periodic Review

Jan 10, 2025, 8:00 AM EST - 1 year ago

Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6

Dec 13, 2024, 7:00 AM EST - 1 year ago

Intensity Therapeutics Registration statement: Registration Filing

Dec 12, 2024, 8:00 AM EST - 1 year ago

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial, INVINCIBLE-4 (SAKK 66/22), at the 2024 San Antonio Breast Cancer Symposium (SABCS)

Nov 21, 2024, 8:00 AM EST - 1 year ago

Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement

Nov 18, 2024, 8:00 AM EST - 1 year ago

Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS)

Nov 13, 2024, 4:06 PM EST - 1 year ago

Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 12, 2024, 6:00 PM EST - 1 year ago

Intensity Therapeutics Quarterly report: Q3 2024

Nov 12, 2024, 6:00 PM EST - 1 year ago

Intensity Therapeutics Earnings release: Q3 2024

Nov 8, 2024, 8:01 AM EST - 1 year ago

Intensity Therapeutics Selected for Oral Podium Presentation in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society (Sarcomas) Meeting

Oct 31, 2024, 9:00 AM EDT - 1 year ago

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22)

Sep 4, 2024, 8:00 AM EDT - 1 year ago

Intensity Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 8, 2024, 4:19 PM EDT - 1 year ago

Intensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 7, 2024, 6:00 PM EDT - 1 year ago

Intensity Therapeutics Quarterly report: Q2 2024

Aug 7, 2024, 6:00 PM EDT - 1 year ago

Intensity Therapeutics Earnings release: Q2 2024

Jul 17, 2024, 10:00 AM EDT - 2 years ago

Intensity Therapeutics Transcript: AGM 2024

Jul 9, 2024, 8:01 AM EDT - 2 years ago

Intensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma

Jul 3, 2024, 8:00 AM EDT - 2 years ago

Intensity Therapeutics Registration statement: Registration Filing

Jul 3, 2024, 8:00 AM EDT - 2 years ago

Intensity Therapeutics Registration statement: Registration Filing

Jun 4, 2024, 8:00 AM EDT - 2 years ago

Intensity Therapeutics Proxy statement: Proxy Filing

Jun 4, 2024, 8:00 AM EDT - 2 years ago

Intensity Therapeutics Proxy statement: Proxy Filing

May 15, 2024, 8:01 AM EDT - 2 years ago

Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors

May 10, 2024, 8:01 AM EDT - 2 years ago

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate

May 9, 2024, 4:08 PM EDT - 2 years ago

Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 8, 2024, 6:00 PM EDT - 2 years ago

Intensity Therapeutics Quarterly report: Q1 2024

May 8, 2024, 6:00 PM EDT - 2 years ago

Intensity Therapeutics Earnings release: Q1 2024

Apr 9, 2024, 10:00 AM EDT - 2 years ago

Intensity Therapeutics Transcript: LD Micro Invitational XIV Conference

Apr 2, 2024, 8:01 AM EDT - 2 years ago

Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024

Mar 14, 2024, 4:09 PM EDT - 2 years ago

Intensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update

Mar 14, 2024, 8:00 AM EDT - 2 years ago

Intensity Therapeutics to Participate in the 36th Annual Roth Conference March 17 to 19, 2024

Mar 13, 2024, 7:00 PM EDT - 2 years ago

Intensity Therapeutics Annual report: Q4 2023

Mar 13, 2024, 7:00 PM EDT - 2 years ago

Intensity Therapeutics Earnings release: Q4 2023

Feb 21, 2024, 8:01 AM EST - 2 years ago

Intensity Therapeutics to Present at the 2024 BIO CEO & Investor Conference

Jan 3, 2024, 8:01 AM EST - 2 years ago

Intensity Therapeutics Provides Business Update Reflecting Progress in Phase 3 Sarcoma Program

Dec 12, 2023, 8:01 AM EST - 2 years ago

Intensity Therapeutics Appoints Joseph Talamo, CPA, as Chief Financial Officer

Jimmyjabba Jun. 4 at 8:07 PM

1 · Reply

Eric1072 Jun. 4 at 3:26 PM

$INTS will buy back in below $2

0 · Reply

Atrain1189 Jun. 4 at 3:19 PM

$INTS what a complete shit show

0 · Reply

SBEEE Jun. 4 at 12:54 AM

$INTS people should bring some of their profits from $SNDK &. $MU, One day INTS is going to be on top with proven Cancer treatment.

1 · Reply

Pettechfl Jun. 4 at 12:23 AM

$INTS whats going on today?

0 · Reply

SBEEE Jun. 3 at 11:30 AM

$INTS Right time for INTS to show performance if CEO is not a vacation anymore. https://finance.yahoo.com/sectors/healthcare/articles/abivax-drops-32-cancer-cases-192613427.html

0 · Reply

SBEEE Jun. 2 at 8:17 PM

$INTS https://www.biopharmaboardroom.com/interaction/1/4546/reprogramming-the-tumor-lew-bender-on-engineering-a-new-paradigm-in-cancer-therapy.html

0 · Reply

Masonic11 May. 29 at 12:02 AM

2 · Reply

Atrain1189 May. 26 at 6:37 PM

$INTS wen moon

1 · Reply

MilsLearning May. 22 at 7:41 PM

$INTS 🩳🔥🖕

0 · Reply

Pettechfl May. 21 at 4:45 PM

$INTS

0 · Reply

Masonic11 May. 20 at 11:48 PM

$ALP $TRNX $TRNFQ $INTS Dear $ALP investor: Throughout the history of this company. There are multiple connections to the many faces of $ALP. There has been intertwined leadership roles with prior management, that didn't end well, with Portage's cancer technology taken private. There is ATON/Portage biotech/BBHC/TRNX / TRNFQ / INTS connections that haven't been brought to light, (yet.) There is amazing IP for clean energy, precious metal recovery, leading to the sterilization of waste water. I initially invested heavily in $TRNX as a young plumber working on large farms, seeing the potential benefits of cleaning up all of the agricultural waste, (large quantities of manure.) I'm all in in this rebrand, as this leadership has the connections we need to be a major player, in confidential computing power. Dive down the rabbit 🐇 hole if you wish. I've been connected with all of this for 7 years...👽

1 · Reply

Masonic11 May. 20 at 11:32 PM

$TRNX $ALP $INTS 👽

0 · Reply

NVDAMillionaire May. 20 at 7:42 PM

$INTS Outstanding article that hits the mark on INTS's current state. So if you want to refresh your INTS insights or learn about INTS from scratch, this is a must read. https://everyticker.com/quote/INTS/analysis/intensity-therapeutics-promising-science-meets-the-funding-cliff-nasdaq-ints

1 · Reply

SBEEE May. 19 at 3:52 PM

$INTS Looks like CEO is leaving for vacation and he’s going to be back on October 1st. WOW. https://www.discoveryontarget.com/drug-modalities

1 · Reply

joel12365 May. 18 at 12:47 PM

$INTS well jelous my average is 10

0 · Reply

ProfitMaker4 May. 18 at 11:54 AM

$INTS continuing to buy sub $5.

0 · Reply

DyllyDylly99 May. 15 at 6:19 PM

$INTS I’m in - good luck to me

1 · Reply

Pettechfl May. 13 at 3:05 PM

$INTS whats with the selling?

1 · Reply

Straightt_Cash_Homie May. 12 at 3:29 PM

$INTS This might be the worst and most suspiciously traded stock i‘ve ever invested in. Hope im wrong.

1 · Reply

TNNSTrade May. 8 at 8:18 PM

$INTS Everything seems on track. We just need to find some momentum. Enjoy the weekend!

1 · Reply

Pettechfl May. 7 at 10:47 PM

https://www.prnewswire.com/news-releases/intensity-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-update-302766229.html $INTS

0 · Reply

Market Cap	10.87M
Revenue (ttm)	0.00
Net Income (ttm)	-11.61M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	37,600
Avg Vol	28,832
Day's Range	N/A - N/A
Shares Out	2.70M
Stochastic %K	20%
Beta	2.77
Analysts	Strong Sell
Price Target	$27.33